FM Nirmala Sitharaman to push biopharma, semiconductor missions in Norway

Finance Minister Nirmala Sitharaman undertook a visit to North America to promote two flagship manufacturing missions announced in Union Budget 2026: Biophar...

What Happened

Finance Minister Nirmala Sitharaman undertook a visit to North America to promote two flagship manufacturing missions announced in Union Budget 2026: Biopharma Shakti and India Semiconductor Mission 2.0.
The diplomatic outreach sought to attract foreign investment, technology partnerships, and market access for these sectors, positioning India as a reliable global manufacturing hub.
Biopharma Shakti is a five-year, ₹10,000 crore programme aimed at boosting domestic production of biologics and biosimilars and establishing India as a global biopharma hub.
India Semiconductor Mission 2.0 (ISM 2.0) was announced with a revised outlay of ₹40,000 crore for the Electronics Components Manufacturing Scheme, focused on semiconductor equipment manufacturing, domestic IP development, and supply chain integration.
The North America visit targeted the US — India's largest trading partner and a key technology and capital source — at a time when India has also signed a framework for an interim trade agreement with the US (February 7, 2026).

Static Topic Bridges

India's Semiconductor Mission and Industrial Policy

Semiconductors — the integrated circuits that power virtually every modern electronic device — have emerged as a defining arena of strategic competition between major powers. India's original India Semiconductor Mission (ISM) was launched in 2021 with a ₹76,000 crore incentive package to attract chip manufacturing to India.

ISM 2.0, announced in Union Budget 2026-27, expands the focus beyond chip fabrication to include semiconductor equipment manufacturing, domestic materials supply, and full-stack Indian semiconductor intellectual property (IP) design.
The Electronics Components Manufacturing Scheme (ECMS) has been enhanced to ₹40,000 crore to capitalise on supply chain diversification away from China.
India's first commercial semiconductor fab is being established in Dholera (Gujarat) by Tata Electronics in partnership with Taiwan's Powerchip Semiconductor Manufacturing Corporation (PSMC), targeting 28nm chips.
A separate fab by CG Power (in collaboration with Japan's Renesas and Thailand's Stars Microelectronics) is planned in Sanand, Gujarat.
ISM 2.0 provides capital subsidies of 15–25% for semiconductor equipment manufacturing, reducing investment burden for companies entering the sector.
24 semiconductor design startups are already supported under the scheme, with ~₹430 crore in venture capital attracted.

Connection to this news: The FM's North America outreach is aimed squarely at persuading American technology firms — facing supply chain pressure to diversify away from Chinese manufacturing — to choose India as a semiconductor partner and investment destination.

Biopharma Shakti and India's Pharmaceutical Sector

India is the world's largest supplier of generic medicines by volume, supplying approximately 20% of global generic drug exports. However, India has historically depended on China for Active Pharmaceutical Ingredients (APIs) — a dependence exposed starkly during the COVID-19 pandemic. Biopharma Shakti targets a new frontier: high-value biologics and biosimilars.

Biologics are medicines derived from biological sources (proteins, antibodies, living cells) rather than chemical synthesis — they include insulin, monoclonal antibodies, and cancer immunotherapies.
Biosimilars are near-identical copies of reference biologics whose patents have expired; they offer significant cost savings for healthcare systems globally.
India currently has a growing biosimilars industry but lacks large-scale domestic biomanufacturing infrastructure; Biopharma Shakti aims to bridge this gap with ₹10,000 crore over five years.
The Indian pharmaceutical industry is worth approximately $50 billion (2025) and is the largest supplier to the US generic drug market, supplying ~40% of US generic prescriptions.
The PLI (Production Linked Incentive) scheme for pharmaceuticals — worth ₹15,000 crore — already incentivises API and formulations manufacturing; Biopharma Shakti complements this for the biologics segment.

Connection to this news: The FM's North America pitch on biopharma targets US healthcare firms and government purchasers (including Medicare/Medicaid) who are under political pressure to reduce drug costs — India's biosimilar manufacturing could serve as a cost-effective partner.

India's Free Trade Agreement Strategy and Export Competitiveness

India's approach to trade liberalisation has historically been cautious, but 2025 marked a turning point with the signing of the India-UK CETA (July 24, 2025) — India's first FTA with a G7 nation — and further agreements with Oman, New Zealand, and a framework accord with the US.

The India-UK CETA (Comprehensive Economic and Trade Agreement), signed July 24, 2025, grants 99% of Indian exports duty-free access to the UK, covering textiles, pharmaceuticals, gems, marine products, and IT services.
UK tariffs on Indian pharmaceutical exports are being eliminated, while India gains fast-track market access with mutual recognition of Good Manufacturing Practices — directly relevant to biopharma.
For semiconductors, FTAs help by reducing input tariffs on equipment and components, enabling Indian fabs to source globally competitive inputs more cheaply.
India's export target is $500+ billion annually by 2030 — up from approximately $437 billion in 2024-25 — driven partly by FTA-enabled market access.

Connection to this news: The FM's North America visit combines FTA diplomacy (the ongoing India-US trade framework) with sectoral mission promotion, recognising that market access agreements and investment attraction are mutually reinforcing for manufacturing sectors like semiconductors and biopharma.

Key Facts & Data

Biopharma Shakti: ₹10,000 crore over five years for biologics and biosimilars manufacturing
India Semiconductor Mission 2.0: announced in Union Budget 2026; Electronics Components Manufacturing Scheme expanded to ₹40,000 crore
ISM 2.0 focus: semiconductor equipment manufacturing, domestic IP, supply chain integration
India-UK CETA signed: July 24, 2025; 99% of Indian exports to UK duty-free
India-US interim trade framework: announced February 7, 2026
India's pharma industry value: ~$50 billion; supplies ~40% of US generic prescriptions
Tata Electronics-PSMC semiconductor fab at Dholera, Gujarat: targeting 28nm chips
ISM capital subsidies: 15–25% for semiconductor equipment manufacturers
India's export target: $500+ billion/year by 2030
PLI scheme for pharmaceuticals: ₹15,000 crore (existing; Biopharma Shakti is additional)